NCT07007780View on ClinicalTrials.gov

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 20, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 30, 2027

Conditions
Triple -Negative Breast Cancer
Interventions
DRUG

Sacituzumab Tirumotecan

Sacituzumab Tirumotecan monotherapy before surgery at a dose of 5mg/kg, with a dosing schedule of once every 2 weeks for a total of 12 weeks

All Listed Sponsors
lead

Xijing Hospital

OTHER